Clinical Trial Update: Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the safety and immunogenicity of EnvSeq-1 and CH505 M5 gp120 Env immunogens with the GLA-SE adjuvant in healthy, HIV-uninfected adults; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CH505 M5 gp120 Env (CH505 M5 gp120 envelope immunogen)
• EnvSeq-1 (EnvSeq-1 immunogen)
• GLA-SE adjuvant (GLA-SE)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2023-02-01